| |||
Names | |||
---|---|---|---|
IUPAC name
2-Aminoguanidine
| |||
Other names
| |||
Identifiers | |||
3D model (JSmol)
|
|||
ChEMBL | |||
ChemSpider | |||
ECHA InfoCard | 100.001.076 | ||
KEGG | |||
PubChem CID
|
|||
UNII | |||
CompTox Dashboard (EPA)
|
|||
| |||
| |||
Properties | |||
CH6N4 | |||
Molar mass | 74.085 g/mol | ||
Density | 1.72 g/ml | ||
Boiling point | 261 °C (502 °F; 534 K) | ||
log P | −1.475 | ||
Related compounds | |||
Related compounds
|
Guanidine | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug.[1] Pimagedine functions as an inhibitor of diamine oxidase and nitric oxide synthase. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, glyoxal, methylglyoxal, and related dicarbonyls. These reactive species are converted to less reactive heterocycles by this condensation reaction.